.png){kind=icon}
.png){kind=icon}
Return
LB1153 Topline results of phase III trial for common warts: efficacy, safety, and systemic response of intralesional candida albicans antigen
.png){kind=icon}
PRE
AI
S
R
DOI：10.1016/j.jid.2026.06.1184.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En
Journal
IF:
5.7
Papers:
1.8W
Citations:
3.4W
Organization
Cited Papers